Thomas McCauley, Ph.D.
About Thomas McCauley, Ph.D.
Thomas McCauley Ph.D. Chief Scientific Officer
Thomas McCauley, Ph.D., serves as the Chief Scientific Officer, bringing extensive expertise in scientific research and development. Dr. McCauley holds a Ph.D. and has a strong background in oncology and therapeutic development. His leadership and scientific acumen drive the company's innovative projects aimed at addressing complex medical challenges.
Thomas McCauley Education and Expertise
Dr. Thomas McCauley holds a Ph.D., positioning him as an expert in his field. His research focuses primarily on oncology, particularly in the modulation of the MYC oncogene using programmable mRNA therapeutics. His expertise extends to developing novel therapies for hepatocellular carcinoma and other solid tumors, showcasing his commitment to advancing cancer treatment through innovative approaches.
Thomas McCauley Background in Cancer Research
Dr. Thomas McCauley has a distinguished background in cancer research. He has contributed to significant advancements in targeted therapies, with a specific focus on the modulation of the MYC oncogene. His work includes research on targeted epigenomic control of MYC as a strategy to treat EGFR inhibitor-resistant non-small cell lung cancer (NSCLC), demonstrating his depth of knowledge in precision oncology.
Thomas McCauley Published Research and Contributions
Dr. Thomas McCauley has made notable contributions to scientific literature. He has co-authored a publication titled 'Drugging the epigenome in the age of precision medicine' in Clinical Epigenetics. His research has been recognized and disseminated through reputable scientific channels, underlining his role in pioneering new therapeutic strategies.
Thomas McCauley Conference Presentations
Dr. Thomas McCauley has presented his research at various prestigious scientific conferences, including the American Society of Gene & Cell Therapy (ASGCT), the American Association for Cancer Research (AACR), the American Association for the Study of Liver Diseases (AASLD), and the American Society of Clinical Oncology (ASCO). These presentations reflect his active engagement with the scientific community and his commitment to sharing knowledge and advancements in cancer therapeutics.